Adolescent breast lymphoma – apparently aggressive presentation with favourable outcome
N Abdullah1, KA Behranwala1, A Wotherspoon1, Gerald PH Gui2, 1 Academic Surgery, Breast Unit, Royal Marsden NHS Trust, Fulham Road, London, United Kingdom 2 Department of Pathology, Breast Unit, Royal Marsden NHS Trust, Fulham Road, London, United Kingdom
Correspondence Address:
Gerald PH Gui Department of Pathology, Breast Unit, Royal Marsden NHS Trust, Fulham Road, London United Kingdom
How to cite this article:
Abdullah N, Behranwala K A, Wotherspoon A, Gui GP. Adolescent breast lymphoma – apparently aggressive presentation with favourable outcome
.J Postgrad Med 2004;50:236-237
|
How to cite this URL:
Abdullah N, Behranwala K A, Wotherspoon A, Gui GP. Adolescent breast lymphoma – apparently aggressive presentation with favourable outcome
. J Postgrad Med [serial online] 2004 [cited 2023 Oct 2 ];50:236-237
Available from: https://www.jpgmonline.com/text.asp?2004/50/3/236/12588 |
Full Text
Sir,
Primary breast lymphoma (PBL) is a rare entity making up less than 0.5% of breast malignancies. The occurrence of PBL in adolescence is rare. Anaplastic large cell lymphoma (ALCL) is an unusual variant with apparently aggressive features. We report such a case with a very favourable long-term outcome.
A 15-year-old girl presented in 1981 with a 5-cm ulcerating lump in her left breast of five months duration (Stage 5 adolescent development). There was no axillary lymphadenopathy [Figure:1]a. Wide local excision with split skin graft coverage was done [Figure:1]b. Grossly, a 5-cm mass of ulcerating pale tissue was seen. Microscopically, sheets of malignant "epithelial" cells with anaplastic arrangement, conspicuous pleomorphism and mitoses were seen [Figure:2]a which was interpreted as a medullary or encephaloid carcinoma. She was treated with oral cyclophosphamide for 31 months and prednisolone for seven months. Neither adjuvant radiotherapy nor tamoxifen was offered. She remains well with two healthy children at 22 years of follow-up.
Review of the histology was done as the patient was referred to our hospital. The blocks were preserved and further sections were cut. Immunostaining was performed using standard procedures with a streptavidin-biotin detection system. Heat-mediated antigen retrieval was used where appropriate. Immunocytochemistry showed that the cells failed to stain with antibodies to cytokeratin (CAM 5.2, AE1/AE3) [Figure:2]b and S100 protein. There was focal staining for epithelial membrane antigen. The cells stained strongly for CD30 [Figure:2]c with positive staining for CD45 in some cells. The cells were negative for T cell, B cell and NK cell markers. The appearances were consistent with the diagnosis of anaplastic large cell lymphoma (ALCL) of the breast of common type with a null phenotype. Staining with ALK-1 gave a characteristic nuclear and cytoplasmic pattern seen in cases with the t (2; 5) translocation associated with this tumour [Figure:2]d. Immunostaining for oestrogen receptor (ER), progesterone receptor (PgR) and Her 2 were negative.
Breast tumours during adolescence are most frequently benign. The rarity of PBL is probably related to the paucity of natural lymphoid tissue in the breast. Diagnostic criteria for PBL set by Wiseman and Liao[1] included 1) technically adequate material for review; 2) the breast as the primary tumour site and 3) no prior documentation of a similar histological type of lymphoma elsewhere. The majority of ALCL cells stain positive for the CD30 and anaplastic large cell lymphoma kinase (ALK) protein, which may also be a useful prognostic factor.[2] The overall 5-year survival rate in ALK-positive tumours is almost 80% in contrast to only 40% in negative tumours. However, these tumours often remain sensitive to chemotherapy. Our patient had an ALK-positive tumour and this probably predicted her long survival. Our patient is of the common variant type according to the Stein[3] subclassification of ALCL.
As PBL is rare, clinical management protocols are often based on the treatment of lymphomas in general. The most common chemotherapy combination for non-Hodgkin lymphoma and non-specified malignant lymphoma is based on the CHOP regime consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone.[4] Although ALCL is associated with good prognosis, long-term follow-up is required. Recurrence may be loco-regional, in the contralateral breast[5] or systemic and occurs in about 30% of cases.
Women presenting with rare breast lymphomas should be accurately diagnosed and the subtype characterised to facilitate optimum treatment and prognosis. ALK-positive ALCL are associated with good prognosis.
References
1 | Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972;29:1705-12. |
2 | Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press; 2001. p. 230-5. |
3 | Stein H, Foss H, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30+ anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95. |
4 | Lyons JA, Myles J, Pohlman B, Macklis RM, Crowe J, Crownover RL. Treatment and prognosis of primary breast lymphoma: A review of 13 cases. Am J Clin Oncol 2000;23:334-6. |
5 | Shapiro CM, Mansur D. Bilateral primary breast lymphoma. Am J Clin Oncol 2001;24:85-6. |
|